objeCtives: In the COU-AA-301 trial, abiraterone acetate with low-dose prednisone (AA) was found to extend survival in metastatic castrate resistant prostate cancer (mCRPC) patients progressing after docetaxel chemotherapy compared to placebo with low-dose prednisone. This study aimed to evaluate AA treatment duration in routine clinical practice in mCRPC patients in four European countries. Treatment sequencing and survival data were assessed to place the treatment duration into context. Results for France and the Netherlands are reported. Methods: The study was designed as a retrospective chart review. Patients were identified through treating oncologists and urologists. Eligible mCRPC patients were aged ≥ 18 years, previously treated with docetaxel and naïve to prior AA treatment. Baseline patient characteristics were described using summary statistics. Kaplan-Meier survival analyses were performed for AA treatment duration, overall survival (OS) and time to prostate-specific antigen (PSA) progression endpoints. Results: A total of 68 physicians (France and the Netherlands) reported data on 269 mCRPC patients treated with AA. Median PSA (ng/mL) of patients from France and the Netherlands at baseline were 56.0 (interquartile range [IQR]: 28.0-120.0) and 174.5 (IQR: 69.5-371.5), respectively. The median time (months) between mCRPC diagnosis and AA initiation was 12.6 (IQR: 7.0-27.2) in France and 18.3 (IQR: 9.6-30.2) in the Netherlands. Median (months) AA treatment duration, median OS and median time to PSA progression in France was 11.3 (95% confidence interval [95%CI]: 8.3-13.7), 21.6 (95%CI: 14.5-.) and 13.8 (95%CI: 11.0-14.7), respectively. In the Netherlands, it was 4.9 (95%CI: 3.4-6.4), 11.0 (95%CI: 7.3-13.0) and 4.9 (95%CI: 3.0-7.3), respectively. ConClusions: Here we describe the real-world treatment of mCRPC patients receiving AA in the post-chemotherapy setting in two EU countries. This study suggests that initiating AA earlier in the post chemotherapy mCRPC setting may result in better health outcomes. To compare adherence, persistence and switching pattern of tyrosin kinase inhibitor (TKIs) imatinib, dasatinib, and nilotinib in patients with newly diagnosed Ph+ CML from Korean national health insurance (NHI) claims database. Methods: Adults newly diagnosed Ph+ CML (ICD-10: C92.1) patients with imatinib, dasatinib, or nilotininb prescription claims between January 1, 2012 and December 31, 2012 were identified form the NHI claims database. The first day of TKI treatment following Ph+ CML diagnosis was defined as the index date. Adherence was measured using Medication possession ratio (MPR) (Poor MPR: < 70%, Good MPR ≥ 90%). Duration of TKI use was determined based on a gap in TKI of ≥ 180 consecutive days after TKI initiation or switch to another TKI within the 180-day window. Results: A total of 304 patients were identified. The 184imatinib patients, the 70 dasatinib patients, and 51 nilotinib patients were similar in mean age, gender and comorbidity at baseline. Based on the 180-day gap definition of discontinuation, it was not significantly different. Mean MPR (imatinib 89.1%, dasatinib 91.2%, nilotinib 91.6%, p-value= 0.4763) and persistency (imatinib 78.7%, dasatinib 88.5%, nilotinib 95.3%, p-value= 0.411) was also not significantly different among three groups. However, switch to second TKI therapy from index TKI in imatinib group was significantly higher than dasatinib and nilotinib (p< 0.001). Patients with Good MPR showed higher survival rate (p= 0.0039) and patients who do not switch to other TKIs showed higher survival rate (p= 0.0040). ConClusions: In a retrospective assessment of patients with CP-CML treated with imatinib, dasatinib and nilotinib, using NHI claims data have shown that imatinib was used more frequently than other TKI in the first-line setting. Furthermore adherence and discontinuation was not different among patients receiving TKI. It would be needed to follow up how treatment decisions for patients with CML are changed over time in routine clinical practice in Korea objeCtives: To determine country-specific requirements for real-world evidence (RWE) in Europe to support ongoing market access for new drugs to treat advanced melanoma. General perception suggests that RWE is crucial for demonstrating long-term value of innovative products. However, it is unclear how these perceptions correlate with absolute requirements of reimbursement agencies. Methods: We reviewed published health technology assessments (HTAs) and reimbursement agency web sites for feasible data sources for melanoma RWE generation and guidance on collecting RWE in Europe. We also performed a pragmatic review of peer-reviewed literature to identify examples of published RWE in melanoma, and sought views of market access specialists from a global pharmaceutical com- objeCtives: This national population-based retrospective study aimed to evaluate the relative effectiveness of adding erlotinib to gemcitabine with pancreatic cancer patients compared to gemcitabine in real clinical practice. Methods: Patients was identified retrospectively using Korean National Health Insurance claims database who pancreatic cancer (ICD-10: C25) who initiated chemotherapy with gemcitabine or erlotinib between January 1, 2007 and December 31, 2012. To be included in the study population, patients were required to have a history of intervention for histologic or cytologic diagnosis within one year before chemotherapy. For homogeneity, patients were excluded if they have diagnosed with other cancers where gemcitabine is indicated or prior radiotherapy or surgical treatment. Results: A total of 4,267 patients were included. Overall survival was not significantly longer in patients treated with gemcitabine/erlotinib (median 6.77 months for gemcitabine/ erlotinib vs. 6.68 months for gemcitabine, p= 0.0977). One-year survival rate was also not significantly different (27.0% vs. 27.3%; p= 0.5988). Based on this relative effectiveness, incremental cost per life year gained over gemcitabine was estimated at USD 70,843.64 for gemcitabine plus erlotinib. ConClusions: Combination of gemcitabine/erlotinib of advanced pancreatic cancer is not more effective than gemcitabine monotherapy in a real-world setting. It does not provide reasonable cost-effectiveness over gemcitabine alone, and reimbursement strategies for pancreatic cancer in Korea could be reconsidered. objeCtives: To assess relative efficacy and safety of second-line treatments in chronic myeloid leukaemia (CML), a systematic review (SR) and network metaanalysis (NMA) feasibility study were conducted. Methods: A SR was conducted in January 2015 (Embase, MEDLINE, Cochrane Library, Clintrials.gov and conferences) to identify comparative trials evaluating treatment outcomes in patients with CML previously treated with tyrosine kinase inhibitors. Eligible studies were examined to assess NMA feasibility. Results: Twenty-three publications relating to six randomised controlled trials (RCTs) on second-line treatment met the eligibility criteria. Included studies compared either nilotinib (n= 3) or dasatinib (n= 1) with imatinib, or studied dasatinib at alternative doses (n= 2). No comparative bosutinib or ponatinib studies were identified. Efficacy outcomes were reported using various definitions and different time points. Compared with nilotinib, significantly fewer imatinib treated patients with complete cytogenetic response (CCyR) at baseline, achieved complete molecular response (CMR) (23% vs 11%, p= 0.02) by 12 and confirmed CMR (22.1% vs 8.7%, p= 0.0087) by 24 months and in patients without major molecular response (MMR) at baseline, MMR by 12 (75% vs 36%, p= 0.006) and 24 (83.3% vs 53.6%, p= 0.0342) months. Compared with imatinib, significantly more dasatinib patients achieved CCyR (16% vs 40%, p= 0.004; 18% vs 44%, p= 0.0025), MMR (4% vs 16%, p= 0.038; 12% vs 29%, p= 0.028) and complete haematologic response (82% vs 93%, p= 0.034; 82% vs 93%, p= 0.0341) at 15 and 24 months, respectively. Interpretation of safety data was inconclusive due to its limited availability and treatment exposure differences. Even considering prospective non-RCTs, NMA was not feasible due to missing network links, significant differences between trial populations, and varying follow-up times. ConClusions: Review of all published comparative studies on second-line treatment of CML confirms that, based on direct efficacy results, dasatinib and nilotinib are the second line agents of choice. NMA comparing nilotinib and dasatinib was not feasible.
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PCN33 mAtChiNg-ADjusteD iNDireCt treAtmeNt ComPArisoN AND survivAl extrAPolAtioN iN rADioioDiNe-refrACtory DiffereNtiAteD thyroiD CANCer (rAi-refrACtory DtC): uPDAteD ANAlysis
Tremblay G 1 , Pelletier C 1 , Forsythe A 2 , Majethia U 2 1 Eisai, Woodcliff Lake, NJ, USA, 2 Eisai Inc., Woodcliff Lake, NJ, USA objeCtives: Indirect treatment comparisons (ITCs) are important when evaluating comparative-effectiveness in absence of head-to-head clinical trials. Classic ITCs can lead to biased results due to differences in patient populations and trial designs. These differences can be corrected for by using matching-adjusted-ITC (MAIC) technique. Furthermore, extrapolation of survival data beyond clinical trial results may be required for economic evaluations. The objective of this research was to compare lenvatinib and sorafenib in patients with RAI-Refractory DTC using MAIC and survival extrapolation techniques. This analysis is an update to the MAIC published previously using a later data cut-off date for both drugs. Methods: Mean overall-survival (OS) and progression-free survival (PFS) outcomes were estimated by weighting patient-level data based on baseline characteristics from individual phase III trials using logistic regression. Classic ITC was performed before and after adjustment. Cross-over correction was also applied. Extrapolation of OS and PFS was performed using proportional hazard, accelerated time failure, individual parametric models and piecewise models. Results were presented as hazard-ratios (HR) with confidence-intervals (CI). 
